Triaksh Enterprises

Humalog Mix 25 Cartridges are a sterile white suspension manufactured by Eli Lilly for the management of type 1 and type 2 diabetes. The formulation consists of a premixed blend containing 25% insulin lispro (a rapid-acting analogue) and 75% insulin lispro protamine suspension (an intermediate-acting analogue). This combination allows the medication to address immediate blood sugar spikes following a meal while simultaneously providing basal coverage to maintain stable glucose levels throughout the day.

The medication is designed specifically for subcutaneous injection and must never be administered intravenously or used in an insulin pump. It is typically injected into the abdomen, thigh, upper arm, or buttocks approximately 15 minutes before a meal. To ensure a consistent dose, the cartridge must be gently rolled and inverted at least ten times until the liquid appears uniformly cloudy or milky before use. Injection sites should be rotated regularly to prevent skin complications such as lipodystrophy (skin thickening or pitting).

Proper storage is critical for maintaining the medication's effectiveness. Unopened cartridges should be kept in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from direct light. Once a cartridge is in use, it should be kept at room temperature (below 30°C or 86°F) and must be discarded after 28 days, regardless of how much insulin remains. It is important to remove the needle after every injection and not store the pen with a needle attached to prevent leaking or contamination.

Humalog Mix 25 is a sterile, white suspension manufactured by Eli Lilly that combines two types of insulin to manage blood sugar in people with type 1 and type 2 diabetes. It consists of 25% insulin lispro, a rapid-acting analogue, and 75% insulin lispro protamine suspension, which acts as an intermediate-acting component. By blending these, the medication provides both immediate mealtime coverage and a sustained basal effect that lasts for up to 24 hours, effectively mimicking the body's natural insulin response to both food intake and background needs.

The medication works by facilitating the uptake of glucose into muscle and fat tissues while simultaneously suppressing the liver's production of sugar. Because the rapid-acting component begins to lower blood sugar within 10 to 15 minutes, it is typically administered just before or even shortly after a meal. This quick onset allows for greater flexibility in meal timing compared to older human insulin mixtures, which often required a much longer wait before eating.

Lirafit is a prescription antidiabetic medication launched by Glenmark Pharmaceuticals in early 2024 as India's first biosimilar of Liraglutide. It is primarily indicated for adults with Type 2 Diabetes Mellitus to improve glycemic control by helping the pancreas release insulin more effectively when blood sugar levels are high. Beyond its primary role in blood sugar management, the drug is used to reduce the risk of major cardiovascular events such as heart attack or stroke in patients with established heart disease.

The medication operates as a GLP-1 receptor agonist, mimicking the natural hormone incretin to stimulate insulin secretion, inhibit glucagon release, and slow down gastric emptying. This mechanism not only prevents post-meal sugar spikes but also acts on the brain's appetite centers to promote a feeling of fullness, which can support weight management in obese or overweight individuals. Clinical trials in India have shown it to be safe and effective, with a safety profile comparable to the original reference drug.

Administered once daily as a subcutaneous injection in the thigh, abdomen, or upper arm, Lirafit is available in a pre-filled pen format for ease of use.

Humalog cartridges, manufactured by Eli Lilly, are clear, colorless, sterile solutions containing insulin lispro at a concentration of 100 units/mL. Each 3 mL glass cartridge holds a total of 300 units of this rapid-acting insulin analog, which is specifically designed for use in compatible Lilly 3 mL insulin pens or certain subcutaneous infusion pumps. The cartridge features a built-in gauge on its side with marks approximately 20 units apart to help users estimate the remaining volume. Patients must inspect the liquid before every injection to ensure it remains water-like in consistency; it should never be used if it appears cloudy, thickened, or contains visible solid particles.

For safety and efficacy, unopened cartridges should be stored in a refrigerator between 2°C and 8°C, while those currently in use should be kept at room temperature (below 30°C) and must be discarded after 28 days. To maintain sterility and prevent dose inaccuracies, the needle should always be removed immediately after each use and the pen stored without it attached.

Gufic's Puretrig 5000 IU (Human Chorionic Gonadotropin or hCG) is an injection primarily used to treat infertility in women and hypogonadism (low testosterone/sperm count) in men. It is a prescription medication that works by stimulating the production of sex hormones.
It helps in the normal development of an egg within the ovary and triggers its release (ovulation), increasing the chance of successful pregnancy. It is often used as part of assisted reproductive technologies like IVF.
In men with low testosterone or a low sperm count, it stimulates the production of testosterone and improves sperm production.
In young boys, it is used to treat undescended testicles, helping them move down into the scrotum.